NGS-based MRD monitoring in mature B-cell and plasma cell malignancies
Academia Molecular Biology and Genomics · 28.05.2026 · 3 (2)
DOI: 10.20935/acadmolbiogen8333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academia Molecular Biology and Genomics, online erschienen am 28.05.2026. Verfasst von Roisin McAvera und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
Minimal residual disease (MRD) is an important prognostic marker in mature B-cell and plasma cell malignancies, providing sensitive assessment of treatment response and risk of relapse. Next-generation sequencing (NGS) enables highly sensitive detection of MRD through identification and tracking of immunoglobulin gene rearrangements associated with malignant clones of B-cell origin. This review outlines the principles of NGS-based MRD assessment and its application in mature B-cell and plasma cell malignancies including several mature B-cell lymphomas, chronic lymphocytic leukaemia (CLL), and multiple myeloma (MM). The advantages of NGS, such as high sensitivity and ability to use a range of sample types, are discussed alongside its limitations, including the requirement for baseline diagnostic samples and cost. Current evidence suggests that NGS is a powerful tool for MRD detection and is increasingly being incorporated into clinical trials as a response endpoint, with potential to guide treatment strategies such as escalation of therapy in routine clinical practice.
Zitieren
APA
McAvera, R., & Glavey, S. (2026). NGS-based MRD monitoring in mature B-cell and plasma cell malignancies. Academia Molecular Biology and Genomics, 3(2). https://doi.org/10.20935/acadmolbiogen8333
Vancouver
McAvera R, Glavey S. NGS-based MRD monitoring in mature B-cell and plasma cell malignancies. Academia Molecular Biology and Genomics. 2026;3(2). doi:10.20935/acadmolbiogen8333
BibTeX
@article{McAvera2026,
author = {McAvera, Roisin and Glavey, Siobhan},
title = {NGS-based MRD monitoring in mature B-cell and plasma cell malignancies},
journal = {Academia Molecular Biology and Genomics},
year = {2026},
volume = {3},
number = {2},
doi = {10.20935/acadmolbiogen8333}
}
EUVIMED